Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
419results about "Polypeptide with affinity tag" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Arrays of protein-capture agents and methods of use thereof
Owner:WAGNER PETER +3
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
InactiveUS7638299B2Improve stabilityPromote circulationVirus peptidesVasoactive intestinal peptideAmino acidBiosynthesis
Owner:AMBRX
Fusion peptides isolatable by phase transition
Owner:PHASE BIOSCIENCE INC
Fusion peptides isolatable by phase transition
InactiveUS20050255554A1Improve scalabilityRecovery conditionPeptide/protein ingredientsAntibody mimetics/scaffoldsBiotechnologyMolecular biology
Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods.
Owner:PHASE BIOSCIENCE INC
Fusion peptides isolatable by phase transition
InactiveUS20010034050A1Small sizePeptide/protein ingredientsHydrolasesPurification methodsThroughput
Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods that produce high yields (e.g., milligram levels) of purified proteins, thereby yielding sufficient purified product for multiple assays and analyses. The high throughput purification technique is simpler and less expensive than current commercial high throughput purification methods, since it requires only one transfer of purification intermediates to a new multiwell plate.
Owner:PHASE BIOSCIENCE INC
Method for regulating protein function in cells using synthetic small molecules
Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
Owner:YALE UNIV
Method for purifying and recovering silk proteins using magnetic affinity separation
A method for the purification of recombinant silk proteins from a sample using magnetic affinity separation is described. The recombinant silk protein is expressed with an affinity tag which has a high binding affinity for an affinity ligand immobilized on magnetic particles. In the method, the processes of clarification of the crude silk protein extract, concentration of the product and purification of the product are combined in a single step involving the affinity capture of the spider silk protein onto the magnetic particles directly from the extract. The product yields are improved due to the reduced number of steps in the purification process.
Owner:EI DU PONT DE NEMOURS & CO
Non-specific binding resistant protein arrays and methods for making the same
InactiveUS20050214855A1Material nanotechnologyBioreactor/fermenter combinationsBiological bodyCell biology
Arrays of protein-capture agents useful for the simultaneous detection of a plurality of proteins which are the expression products, or fragments thereof, of a cell or population of cells in an organism are provided. A variety of antibody arrays, in particular, are described. Methods of both making and using the arrays of protein-capture agents are also disclosed. The invention arrays are particularly useful for various proteomics applications including assessing patterns of protein expression and modification in cells.
Owner:ZYOMYX
Pharmaceutical compositions comprising elp fusion proteins
InactiveUS20090220455A1Improve scalabilityEquipment eliminatedPeptide/protein ingredientsAntibody mimetics/scaffoldsPurification methodsPeptide
Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods.
Owner:PHASEBIO PHARMA INC
Method for regulating protein function in cells using synthetic small molecules
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Truncated St6galnaci Polypeptides and Nucleic Acids
Owner:NOVO NORDISK AS
Functionalized TGF-beta fusion proteins
This disclosure relates to TGF-beta family protein fusions that display substantial native TGF-beta family protein function while also having an additional functionality conveyed by the addition of a functionalizing peptide domain. Such functionalizing peptide domain can be a tag peptide (e.g., an epitope tag, a purification tag, a molecular size differentiation tag, etc.) or a passenger or targeting protein. Also provided are methods of making these fusions, as well as methods of using them for diagnosis and diagnosis of various conditions, in measuring and monitoring levels of the fusion molecule in experimental systems and subjects, and in measuring and detecting receptor proteins.
Owner:GOVERNMENT OF THE UNITED STATE OF AMERICA AS REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES THE
Rna-guided nucleic acid modifying enzymes and methods of use thereof
Owner:RGT UNIV OF CALIFORNIA
Auto-stimulating cells and methods for making and using the same
Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and / or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. In an additional aspect of the invention, methods of making fusion proteins having cis signaling capabilities, as well as the ability to bind with receptors on the cell's own surface, are provided. Fusion proteins incorporating GPI or a homing element, and a costimulator or inhibitor domain can also be directly transferred to the cell surface. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
Owner:RATIOPHARM GMBH
Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
InactiveUS20050032173A1Polypeptide with localisation/targeting motifSugar derivativesPeptide sequenceApoptosis
An isolated fusion protein. In one embodiment of the present invention, the isolated fusion protein includes a membrane-translocating peptide sequence of about 8 to about 50 residues comprising at least eight consecutive residues of SEQ ID NO: 1 (Ala-Ala-Val-Leu-Leu-Pro-Val-Leu-Leu-Ala-Ala-Pro), and an inhibitory IκB protein. Alternatively, the membrane-translocating sequence can have at least 9, 10, 11 or 12 twelve consecutive residues of SEQ ID NO: 1. The isolated infusion protein can be used to treat or prevent an immune response associated with an immune disorder or a disease or disorder related to apoptosis, such as cancer, in a host.
Owner:EMORY UNIVERSITY
Intein-mediated protein purification using in vivo expression of an aggregator protein
InactiveUS20060141570A1Function increaseSuitable for high through-put screeningSugar derivativesBacteriaInteinADAMTS Proteins
Purification of recombinant proteins is performed by expressing in a host cell a fusion protein comprising: (a) a product protein domain, (b) an intein, and (c) at least one aggregator protein domain, wherein the aggregator protein domain comprises a protein that is capable of specific association with granules of polyhydroxyalkanoate (PHA).
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1
Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
ActiveUS20140234348A1Stimulate immune responseAntibody mimetics/scaffoldsTissue cultureAntigenAutoimmune responses
The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Fusion proteins for inhibition and dissolution of coagulation
InactiveUS20090130104A1Local releasePolypeptide with affinity tagImmunoglobulins against animals/humansSide effectThrombus
Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
ActiveUS20180169109A1Rapid cell deathOrganic active ingredientsFusion with degradation motifTumor lysis syndromeTumor Syndrome
This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
Owner:DANA FARBER CANCER INST INC
Application of nucleic acid construct containing streptavidin elements to protein expression and purification
ActiveCN110408635APolypeptide with affinity tagHybrid peptidesBiotin-streptavidin complexForeign protein
The invention provides application of a nucleic acid construct containing streptavidin elements to protein expression and purification, and particularly provides the nucleic acid construct. The nucleic acid construct has a formula I structure from 5' to 3', and the formula I is as follows: Z1-Z2-Z3 (I); and in the formula I, Z1, Z2 and Z3 are the elements used for constituting the construct correspondingly, all '-' are bonds or nucleotide connection sequences independently, Z1 represents a coding sequence of a tag protein, Z2 represents a connection sequence, and Z3 represents a coding sequence of a passive protein or a foreign protein. By applying the nucleic acid construct to a protein synthesis system (especially an in-vitro protein synthesis system), expression and purification of theforeign protein can be completed, and an RFU value of the synthesized foreign protein is increased.
Owner:KANGMA SHANGHAI BIOTECH LTD
Tunable endogenous protein degradation
ActiveUS20180179522A1Negative consequencePermanently editing a gene can be avoidedOrganic active ingredientsFusion with degradation motifProtein targetNucleotide
Owner:DANA FARBER CANCER INST INC
Chaperonin-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release formulation, and method of producing antibody against target protein
InactiveUS20070059794A1Excessive immune responseEfficient executionSugar derivativesHydrolasesProtein targetChaperonin
The present invention provides a chaperonin-target protein complex and a method of producing the same, and a method of stabilizing the target protein, a method of immobilizing the target protein, a method of analyzing the structure of the target protein, a sustained-release formulation, and a method of producing an antibody against the target protein. The chaperonin-target protein complex in the present invention includes a fusion protein having a chaperonin subunit and an affinity tag linked to the chaperonin subunit via a peptide bond and a target protein for which the affinity tag shows a specific affinity, wherein the target protein is bound to the affinity tag by means of the specific affinity, thereby forming a chaperonin ring structure consisting of a plurality of chaperonin subunits. The chaperonin-target protein in the present invention stabilizes the target protein and surely immobilize on a carrier without causing any change in its stereostructure.
Owner:SEKISUI CHEM CO LTD
Array devices and methods of use thereof
InactiveUS20050100947A1Bioreactor/fermenter combinationsMaterial nanotechnologyBiological bodyProteomics
Arrays of protein-capture agents useful for the simultaneous detection of a plurality of proteins which are the expression products, or fragments thereof, of a cell or population of cells in an organism are provided. A variety of antibody arrays, in particular, are described. Methods of both making and using the arrays of protein-capture agents are also disclosed. The invention arrays are particularly useful for various proteomics applications including assessing patterns of protein expression and modification in cells.
Owner:ZYOMYX
Methods using O6-alkylguanine-DNA alkyltransferases
ActiveUS7939284B2Consider flexibilityIn-vivo radioactive preparationsPolypeptide with affinity tagCross linkerIn vivo
A method using O6-alkylguanine-DNA alkyltransferases (AGT) is disclosed for transferring a label from a substrate to a fusion protein comprising the AGT. This allows the detection and / or manipulating of the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such molecules are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilisation of the fusion protein.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Rna-guided nucleic acid modifying enzymes and methods of use thereof
Owner:RGT UNIV OF CALIFORNIA
Soluble TCR molecules and methods of use
ActiveUS20050214284A1Reduced lung metastasisGreat cancer therapeuticImmunoglobulin superfamilyAntibody mimetics/scaffoldsPeptide antigenCancer cell
Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.
Owner:ALTOR BIOSCIENCE CORP
Method for purifying albumin
ActiveUS20120149873A1Increase the gapIncrease productionAntibody mimetics/scaffoldsPolypeptide with affinity tagImproved methodAlbumin
An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed.
Owner:ALBUMEDIX LIMITED
Recombinant fusion proteins with high affinity binding to gold and applications thereof
InactiveUS20060246426A1Robust and efficient immobilizationIncrease the number ofBioreactor/fermenter combinationsBiological substance pretreatmentsBinding peptideAlloy
The present invention provides a method to firmly attach any polypeptide to a gold surface regardless of its intrinsic gold-binding properties. The method describes the production of recombinant fusion proteins consisting of polypeptides of interest and a high affinity gold binding peptide consisting of 1 to 7 repeats of a unique amino acid sequence. By this method, many biologically active polypeptides lacking intrinsic gold-binding properties can be firmly attached to gold surfaces. The disclosure includes evidence that fusion proteins containing the gold-binding sequences provide superior stability and activity compared to similar molecules lacking the tag when used to construct biosensors. The invention provides a method that is a significant improvement over existing chemical and physical adsorption protocols to attach polypeptides to gold and, therefore, can provide benefits to many applications utilizing gold.
Owner:BIOHESION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com